bioAffinity Technologies Inc. has launched a validation study with Brooke Army Medical Center to assess the use of its CyPath Lung test on sputum samples collected via tracheal and bronchial suctioning. The study is expected to enroll about 30 to 50 patients, with results anticipated by mid-2026, and could broaden sample collection options to support earlier lung cancer detection.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260225252955) on February 25, 2026, and is solely responsible for the information contained therein.
Comments